ORAL DELIVERY OF ANTISENSE CONJUGATES TARGETING PCSK9

The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin. L...

Full description

Saved in:
Bibliographic Details
Main Authors SHEAR, CHARLES LESTER, OERUM, HENRIK, NOBLE, STEWART ALWYN
Format Patent
LanguageEnglish
French
Published 16.06.2022
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides pharmaceutic compositions for oral delivery comprising an antisense oligonucleotide (e.g., CIVI 008) and an oral delivery agent such as 5-CNAC. In some aspects, the disclosure provides a capsule comprising a dry blend of CIVI 008 and 5-CNAC, and optionally a statin. La présente invention concerne des compositions pharmaceutiques pour administration orale comprenant un oligonucléotide antisens (par exemple, la CIVI 008) et un agent d'administration orale tel que le 5-CNAC. Dans certains aspects, l'invention concerne une capsule comprenant un mélange sec de CIVI 008 et de 5-CNAC, et facultativement une statine.
Bibliography:Application Number: CA20213200564